New EU rules on short-stay visas apply worldwide from 2 February 2020. They make it easier for legitimate travellers to apply for a visa to come to Europe, facilitating tourism, trade and business, while providing more resources for countering irregular migration risks and threats to internal security.
Which non-EU countries do the new rules apply to?
The changes apply to travellers from all countries which need visas to travel to the EU. Currently, citizens from 105 non-EU countries or entities are required to have a visa (full list available online). Nothing changes for countries benefitting from visa-free travel to the EU because the new rules do not apply to their citizens.
Which destination countries are covered by the update?
The rules cover short-stay visas for the 22 EU countries that are part of the Schengen area (Austria, Belgium, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Slovakia, Slovenia, Spain and Sweden), as well as for four associated countries: Iceland, Liechtenstein, Norway and Switzerland.A uniform short-stay visa issued by one of these countries covers travel throughout the 26 Schengen countries for up to 90 days in any 180-day period.
Why change the EU visa rules now?
The European Parliament and the Council agreed the changes in June 2019.
The tourism and travel industry plays a key role in the European economy. EU Member States are among the world’s leading tourist destinations – the number of visa applications processed has increased considerably over the last 9 years and continues to expand. Since 2009, the number of applications for EU visas has risen by 57% – from 10.2 million to over 16 million in 2018. At the same time, visa application procedures have not changed since 2010 and there was a need to make them less cumbersome, while maintaining the same level of security and control.
Visa fees have not been adapted since 2006 and a €60 fee no longer covers the costs of processing applications, in particular due to inflation.
Finally, by creating a link between visa procedures and cooperation on readmission, the revision gives the EU new tools for a dialogue with partner countries about migration. This possibility is part of the EU’s ongoing efforts in favour of a comprehensive and effective migration policy.
What are the main benefits for travellers?
With the new rules, travellers now benefit from a simpler and more user-friendly visa application procedure:
Visa applications can be submitted up to 6 months before the intended travel (9 months for seafarers), instead of 3 months previously, allowing travellers to better plan their trips;
Multiple-entry visas with long validity (from 1 to 5 years) are now easier to obtain, saving frequent travellers time and money, as they will have to apply for a new visa less often;
In most cases, an application can be submitted directly in the traveller’s country of residence, and where possible filled in and signed electronically (only hard copies were accepted until now), which will also save travellers time, money and hassle.
What are the new rules for issuing multiple-entry visas?
Frequent travellers with a positive visa history are to be granted multiple-entry visa with a gradually increasing validity period from 1 year to a maximum of 5 years.
Travellers’ fulfilment of entry conditions will be thoroughly and repeatedly verified in all cases, and only persons with a positive visa track record will be issued multiple-entry visas with a long validity.
Multiple-entry visas allow the holder to travel repeatedly to the EU during the period of validity of the visa.
How long will it take for the visa application to be processed?
The maximum time for visa applications to be processed remains unchanged at 15 days. The processing time may be longer only in individual cases, for instance where further scrutiny of the application is needed, and take up to maximum 45 days.
With which consulate should applicants lodge their visa application?
The rules remain the same. Applicants must lodge their application at the consulate of the country they intend to visit. Applicants planning to visit several Schengen states must apply at the consulate of the country where they will spend the longest period. Applicants planning on visiting several Schengen states for equal lengths of stay must apply at the consulate of the country whose external borders they will cross first when entering the Schengen area.In case the Schengen state of destination has no consulate in the country where the applicant resides, the applicant should check whether it is represented by another consulate.
Do visa applicants have to submit their application in person at a consulate?
In most cases, visa applications can be submitted in the applicant’s country of residence (either at a consulate or at the premises of an external service provider) and, where possible, the application form can be filled in and signed electronically. Under the new rules, applicants have to appear in person only when fingerprints are to be collected (i.e. every 59 months).
Can the application be submitted via an external service provider?
Most Member States use external service providers to collect visa applications and supporting documents. The large network of “visa application centres” means that applicants do not usually have to travel too far to lodge their application. Member States remain fully responsible for processing and deciding on visa applications.
What are the requirements for applying for a short stay visa?
The rules have not changed. In order to apply for a short stay visa to the EU, applicants must present:
A filled in and signed visa application form;
A passport issued in the last 10 years and valid for at least 3 months after the end of the stay;
An identity photograph;
Proof of possession of adequate and valid travel medical insurance;
Supporting documents relating to the purpose of the stay, evidence of means of support during the stay and accommodation.
Applicants must also pay the visa fee and, where applicable, have their fingerprints collected.
Do visa applicants need a travel medical insurance when travelling to the EU?
Yes, visa applicants must present a valid travel medical insurance when applying for a visa, as it was already the case under the previous rules.
What is the amount of the visa fee? What will the increased visa fee be used for?
The visa fee increases from €60 to €80. This increase is the first one since 2006 and it brings the fee in line with the level where it would be today if it had been aligned to the general EU-wide inflation rate since 2006.
The €60 fee no longer adequately covered the administrative costs (such as staffing, premises and equipment) for offering adequate service to the constantly growing numbers of applications. The increase in the visa fee will ensure there are sufficient financial resources to maintain a wide consular coverage worldwide and reinforce consular staff, speed up the application process and provide better quality service for travellers, upgrade IT equipment and software, and improve the capacity to detect potential security and irregular migration risks.
Importantly, for regular travellers, the fee increase will be partly offset by the new rules on long-validity visas: these travellers may actually save money under the new provisions, since they have to apply for visas less often.
Will the visa fee also increase for countries benefiting from lower fees under Visa Facilitation Agreements?
No. The increase of the general visa fee has no impact on the lower visa fee (€35) set in the Visa Facilitation Agreements concluded between the EU and a number of third countries, such as Armenia, Azerbaijan and Russia.
How does the revised visa fee compare to the fees charged by other countries?
By international standards, the €80 visa fee remains low. As a comparison, applying for a tourist visa to the United States costs €143 and €126 for China. Travellers to Australia have to pay €90 for their visa, while those going to New Zealand will be charged €146. A visa to Canada costs €68, to India €95, and to the UK €112 (January 2020).
Are there any visa fee waivers and reductions?
Yes, the visa fee is still waived for children below 6 years old, as was already the case under the previous rules. The visa fee for minors between the age of 6 and 12 years remains half of the general fee, and thus increases by €5 (to €40). In addition, it is now possible for Member States to waive the visa fee for minors between the age of 6 and 18 years.
How will the cooperation on readmission be linked to EU visa policy?
Over the past years, the EU has been stepping up activities to support Member States in returning people who have no right to stay in Europe. Even though readmission of own nationals is an obligation under international law, Member States have experienced difficulties in returning irregular migrants.
The revised visa rules introduce a new mechanism linking visa policy and cooperation on readmission. This will bring an important element into the EU’s discussions with partner countries.
Under the new rules, the Commission will conduct a regular assessment of how non-EU countries cooperate on readmission, taking into account indicators such as:
The number of return decisions issued to citizens of a given non-EU country;
The number of actual returns as a percentage of the number of return decisions issued;
The number of readmission requests accepted by the non-EU country as a percentage of the number of requests submitted to it; and
The level of practical cooperation in the different stages of the return procedure, including as regards the assistance provided in the identification of persons irregularly staying in the EU and the timely issuance of travel documents.
Member States which encounter substantial and persistent readmission problems with a given non-EU country may also notify the Commission of such a situation. In such cases, the Commission must assess the notification within one month.
On this basis, the Commission, together with Member States, can establish a more restrictive and temporary implementation of certain provisions of the Visa Code for the processing of visa applications from nationals of the country in question, such as the processing time, the length of validity of visas, the level of the visa fee and the fee waivers.
If a third country cooperates sufficiently on readmission, and taking account of the Union’s overall relations with the third country concerned, the Commission may also propose a more generous implementation of certain provisions of the Visa Code (lower visa fee, quicker processing times and multiple-entry visas with longer validity to be agreed upon by Member States in the Council).
Can nationals of non-EU countries which do not cooperate on readmission still apply for and obtain a visa to travel to the EU?
More restrictive implementation of certain procedural rules and the general rules on the issuing of multiple-entry visas will not call into question applicants’ basic right to submit an application for a visa or to be granted a visa.
When the Commission, together with the Member States, decides that the mechanism should be triggered, the restrictive implementation of certain rules will be adapted to the particular situation in each non EU-country. This could have an impact on the processing time, the length of validity of the visa to be issued, the level of the visa fee to be charged and the fee waivers.
Will the new rules affect the UK after the end of the transition period?
No. In 2019, the Visa Regulation was amended to grant UK nationals visa-free travel to the EU after the United Kingdom’s withdrawal from the European Union. This means that UK nationals will remain visa-free when travelling to the EU for short stays, so the revised visa rules will not apply to them.
Coronavirus: EU Strategy for the development and availability of therapeutics
The European Commission is today complementing the successful EU Vaccines Strategy with a strategy on COVID-19 therapeutics to support the development and availability of much-needed COVID-19 therapeutics, including for the treatment of ‘long COVID’. Today’s Strategy covers the full lifecycle of medicines: from research, development and manufacturing to procurement and deployment.
It is part of the strong European Health Union, in which all EU countries prepare and respond together to health crises and ensure the availability of affordable and innovative medical supplies – including the therapeutics needed to treat COVID-19.
The Strategy includes clear actions and targets, including authorising three new therapeutics to treat COVID-19 by October 2021 and possibly two more by end of the year. Concretely:
- Research, development and innovation
- Invest €90 million in population studies and clinical trials to establish links between risk factors and health outcomes to further inform public health policy and clinical management, including for long-COVID patients.
- Set up a ‘therapeutics innovation booster’ by July 2021 to support the most promising therapeutics from preclinical research to market authorisation. It will build on current initiatives and investments in therapeutic development, working in a close cooperation with the European Health Emergency Preparedness and Response Authority (HERA) preparatory action on mapping therapeutics. It will therefore ensure the coordination of all research projects on COVID-19 therapeutics, stimulating innovation and boosting therapeutic development.
- Access to and swift approval of clinical trials
- Invest €5 million under the EU4Health programme to generate better, high-quality safety data in clinical trials, which will help produce robust results in a timely manner.
- Provide EU countries with financial support of €2 million under the EU4Health 2021 work programme for expedited and coordinated assessments to facilitate approval of clinical trials.
- Explore how to support developers of therapeutics to build capacity to produce high-grade material for clinical trials.
- Scanning for candidate therapeutics
- Invest €5 million to map therapeutics and diagnostics to analyse development phases, production capacities and supply chains, including possible bottlenecks.
- Establish a broader portfolio of 10 potential COVID-19 therapeutics and identify five of the most promising ones by June 2021.
- Supply chains and delivery of medicines
- Fund a €40 million preparatory action to support flexible manufacturing and access for COVID-19 therapeutics under the EU Fab project, which in turn will become over time an important asset for the future the European Health Emergency Preparedness and Response Authority (HERA).
- Regulatory flexibility
- Authorise at least three new therapeutics by October and possibly two more by the end of the year and develop flexible regulatory approaches to speed up the assessment of promising and safe COVID-19 therapeutics.
- Start seven rolling reviews of promising therapeutics by end-2021, subject to research and development outcomes.
- Joint procurement and financing
- Launch new contracts for the purchase of authorised therapeutics by the end of the year.
- Secure faster access to medicines with shorter administrative deadlines.
- International cooperation to make medicines available to all
- Reinforce engagement for the therapeutics pillar of the Access to COVID-19 Tools Accelerator.
- Boost ‘OPEN’ initiative for international collaboration.
The Commission will draw up a portfolio of 10 potential COVID-19 therapeutics and by June 2021, identify the five most promising ones. It will organise matchmaking events for industrial actors involved in therapeutics to ensure enough production capacity and swift manufacturing. New authorisations, rolling reviews and joint procurement contracts will be up and running before the end of the year.
The therapeutics innovation booster, matchmaking events and preparatory action to support flexible manufacturing and access for COVID-19 therapeutics under the EU Fab project, will feed into the HERA, for which a proposal is due later in the year. The pilot project on access to health data will feed into the European Health Data Space proposal expected later this year.
Members of the College said:
Vice-President for Promoting our European Way of Life, Margaritis Schinas, said: “The situation in many intensive care units across the continent remains critical. We need to focus both on vaccines and therapeutics, as two powerful and complementary ways to combat COVID-19. But currently we have only one authorised medicine to treat COVID-19. By acting on better availability of medicines today, we are making sure patients receive the treatments they need while also preparing our future biomedical preparedness. A coordinated strategy on quick access to therapeutics will boost our strategic autonomy and contribute to a strong Health Union.”
Commissioner for Health and Food Safety, Stella Kyriakides, said: “Vaccinations save lives, but they cannot yet eradicate COVID-19. We need a strong push on treatments to limit the need for hospitalisation, speed up recovery times, and reduce mortality. Patients in Europe and across the world should have access to world-class COVID-19 medicines. This is why we have set a very clear goal: by October, we will develop and authorise three new effective COVID-19 therapeutics that can have the potential to change the course of the disease. We will do so by investing in research and innovation, the identification of new promising medicines, ramping up production capacity and supporting equitable access. Our Therapeutics Strategy is a strong European Health Union in action.”
Commissioner for Innovation, Research, Culture, Education and Youth, Mariya Gabriel, said: “By increasing vaccine availability across Europe, more and more Europeans are now protected against COVID-19. In the meantime, the development of innovative medicines to treat coronavirus patients remains a priority when it comes to saving lives. Research and innovation is the first step to finding effective and safe therapeutics, which is why we are proposing to establish a new COVID-19 ‘therapeutics innovation booster’ and will invest € 90 million in population studies and clinical trials.”
The Strategy on COVID-19 therapeutics complements the EU strategy for COVID-19 vaccines from June 2020 and builds on ongoing work by the European Medicines Agency and the Commission to support research, development, manufacturing and deployment of therapeutics.
The Strategy forms part of a strong European Health Union, using a coordinated EU approach to better protect the health of our citizens, equip the EU and its Member States to better prevent and address future pandemics, and improve the resilience of Europe’s health systems.
EU defence gets a boost as the European Defence Fund becomes a reality
Commission welcomes the adoption of the European Defence Fund (EDF), following the European Parliament’s approval. The EDF, with a budget of €7.9 billion, is the Commission’s flagship instrument to support defence cooperation in Europe. EDF will co-finance collaborative research and capability development projects amplifying national investment. It will also foster an innovative and competitive defence industrial base. In doing so, it will enhance Union’s technological sovereignty and therefore its open strategic autonomy.
Margrethe Vestager, Executive Vice-President for a Europe Fit for the Digital Age, said: “This is an important step for a stronger Europe. The Fund will play a key role to enable SMEs to participate in defence supply chains and widen cross-border industrial cooperation. Providing opportunities to companies all sizes helps achieving more innovative solutions, to foster an open internal market. So besides a stronger defence cooperation it contributes to our competitiveness.”
Thierry Breton, Commissioner for Internal Market, said: “Today marks a historic day for Europe. The idea of working together for promoting our Defence Union and for the security of EU citizens is now a tangible reality. In a global context where Europe needs to be stronger, more resilient and more autonomous in strategic areas, the European Defence Fund is a milestone and will significantly contribute to the security of EU citizens.”
A Fund to deepen EU defence industrial cooperation
Without substituting Member States’ efforts, the Fund will promote cooperation between companies of all sizes and research actors throughout the EU, in research and development of state-of-the-art and interoperable defence technology and equipment.
The Fund will support competitive and collaborative defence projects throughout the entire cycle of research and development, focusing on projects that have the potential to be game-changers for the armed forces of Member States. The Fund will foster innovation and incentivise the cross-border participation of SMEs. Projects will be defined based on defence capability priorities agreed by Member States within the framework of the Common Security and Defence Policy and particularly in the context of the Capability Development Plan. The projects will aim at contributing to the security and defence interests of the Union.
The EDF allows for the participation of European subsidiaries of third country companies and also for the cooperation with third country companies provided that their involvement ensure the security and defence interests of the EU, and meet the rigorous security conditions as set in the EDF Regulation.
A strong budget for ambitious and inclusive defence programmes
2021 constitutes the first year of the rollout of the new EDF, which will be operational for the period 2021-2027, in alignment with the Multiannual Financial Framework.
It will be endowed with a budget of €7,953,000,000 in current prices. This financial envelope will be divided into two pillars: €2,651,000,000 will be allocated to funding collaborative defence research to address emerging and future security threats and €5,302,000,000 to co-finance collaborative capability development projects.
Up to 4%-8% of the Fund budget is devoted to development or research for disruptive technologies (i.e. technologies that have the potential to create game-changing innovations). This budget represents an unprecedented opportunity to contribute to the development of a competitive and innovative European defence industry.
The complete establishment of the Fund both legally and financially will now allow the Programme Committee (PC), chaired by the Commission and composed of Member States representatives, to discuss priorities and confront topics with the aim to open calls for proposals in summer 2021. The Commission will directly manage the programme. The European Defence Agency (EDA) is invited to participate as observer and the European External Action Service (EEAS) will assist in the Committee.
The creation of a European Defence Fund was first announced in 2016. The Commission presented the first version of the European Defence Fund in June 2017, which has allowed defence cooperation at EU level to embark thanks to two pilot projects, the Preparatory Action on Defence Research (PADR) for 2017-2019 and the European Defence Industrial Development Programme (EDIDP) for 2019-2020.
The Fund is part of the priorities of the von der Leyen Commission for a ‘Stronger Europe in the World’.
A political agreement between the Member States and the European Parliament was found in December 2020 and today’s decision gives legislative effect to the EDF that will operate for the next 7 years.
Dual-use goods: what are they and why are new rules needed?
The EU is working on new export rules for so-called dual-use goods to prevent them being misused in human rights violations.
What are dual-use goods?
Dual-use products are goods designed for civilian use that in the wrong hands could be used to supress human rights or launch terrorist attacks. They can be anything from drones to chemicals.
Although these goods can improve people’s lives, they can be misused. Authoritarian regimes might use them to keep the population under control, while terrorist groups could use them to stage attacks.
Why are new rules needed?
To prevent dual-use goods being repurposed in ways that violate human rights , the EU wants to make sure strict export rules prevent them being sold to people or organisations wanting to misuse them.
The EU is currently working on an update of the existing rules to take into account recent technological developments, including new cyber surveillance tools, and beef up protection of human rights.
Political Lessons from Kerala: People’s Response to the Communist Welfare System
Amid covid-19 fears, the elections to the legislative assemblies of four Indian states- West Bengal, Tamil Nadu, Assam and Kerala,...
5th Generation Warfare: A reality or Controversy?
In the truest sense, the constant repetition of phrase ‘the 5th generation warfare’ by our military leaders in every media...
Has Modi Conceded ‘South Asia’ to the United States?
Prime Minister Narendra Modi has been pursuing an assertive and confrontational foreign policy. From carrying out ‘surgical strikes’ across the...
Angelus U30 Black Titanium: The one-of-a-kind mean machine
Offered up on the altar of the grande complication, the U30 is a piece like no other. Ultra-light and ultra-sporty,...
Conflict Affected Families in Armenia to Receive World Bank Support
A Grant Agreement for the “Support to Conflict Affected Families” project was signed today by Sylvie Bossoutrot, World Bank Country...
Russia becomes member of International Organization for Migration
After several negotiations, Russia finally becomes as a full-fledged member of the International Organization for Migration (IOM). It means that...
Cut methane emissions to avert global temperature rise
Methane emissions caused by human activity can be reduced by up to 45 per cent this decade, thus helping to...
South Asia3 days ago
The World Biggest COVID-19 Crisis: Failure of India’s Vaccine Diplomacy
Energy2 days ago
Nord Stream 2: To Gain or to Refrain? Why Germany Refuses to Bend under Sanctions Pressure
Defense2 days ago
China’s quad in the making: A non-conventional approach
Americas3 days ago
Trump Lost, Biden Won. Is Joe Biden’s presidency a signal towards Obama’s America?
South Asia2 days ago
Covid19 mismanagement in India
Green Planet3 days ago
Climate Change Problem: an Emerging Threat to Global Security
Reports2 days ago
Clean energy demand for critical minerals set to soar as the world pursues net zero goals
Reports2 days ago
Global e-commerce jumps to $26.7 trillion, fuelled by COVID-19